Click here to view online. Add this email to your safelist.

AstraZeneca logo

AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma

10 January 2018

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2018

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.